Phase Ia study of SYNT001 in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs SYNT 001 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Syntimmune
- 01 Nov 2017 Results presented in an Syntimmune media release.
- 01 Nov 2017 According to a Syntimmune media release, data from this trial will be presented at the 59th American Society of Hematology (ASH) Annual Meeting.
- 28 Mar 2016 New trial record